Stoke Therapeutics (NASDAQ:STOK) Stock Price Down 8.3% - What's Next?

Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) fell 8.3% during trading on Friday . The stock traded as low as $12.72 and last traded at $12.77. 244,843 shares were traded during mid-day trading, a decline of 67% from the average session volume of 751,949 shares. The stock had previously closed at $13.92.

Wall Street Analyst Weigh In

Several analysts have weighed in on STOK shares. HC Wainwright reiterated a "buy" rating and issued a $35.00 price objective on shares of Stoke Therapeutics in a research note on Wednesday, November 6th. Leerink Partnrs upgraded Stoke Therapeutics to a "strong-buy" rating in a research note on Friday, October 11th. Needham & Company LLC restated a "buy" rating and set a $22.00 price objective on shares of Stoke Therapeutics in a research note on Wednesday, November 6th. Finally, Leerink Partners began coverage on Stoke Therapeutics in a report on Monday, October 14th. They issued an "outperform" rating and a $18.00 price objective for the company. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $20.83.

Stoke Therapeutics Stock Performance

The stock has a fifty day simple moving average of $13.06 and a two-hundred day simple moving average of $13.78. The stock has a market cap of $637.23 million, a price-to-earnings ratio of -5.73 and a beta of 0.95.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last announced its quarterly earnings data on Tuesday, November 5th. The company reported ($0.47) earnings per share for the quarter, topping the consensus estimate of ($0.52) by $0.05. The business had revenue of $4.89 million during the quarter, compared to the consensus estimate of $3.46 million. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. Equities analysts expect that Stoke Therapeutics, Inc. will post -2.03 earnings per share for the current fiscal year.

Insider Activity

In other news, major shareholder Skorpios Trust sold 1,937,500 shares of the stock in a transaction on Thursday, September 19th. The stock was sold at an average price of $14.05, for a total value of $27,221,875.00. Following the completion of the transaction, the insider now directly owns 8,906,181 shares in the company, valued at approximately $125,131,843.05. This represents a 17.87 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 11.30% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Stoke Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Quest Partners LLC acquired a new stake in shares of Stoke Therapeutics during the second quarter valued at about $29,000. Nisa Investment Advisors LLC increased its position in Stoke Therapeutics by 53.2% in the 2nd quarter. Nisa Investment Advisors LLC now owns 2,989 shares of the company's stock valued at $40,000 after acquiring an additional 1,038 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in shares of Stoke Therapeutics during the second quarter valued at $123,000. State Board of Administration of Florida Retirement System acquired a new position in shares of Stoke Therapeutics during the first quarter worth $141,000. Finally, Intech Investment Management LLC bought a new stake in shares of Stoke Therapeutics in the third quarter worth $160,000.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.